Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

This study tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation treatment improves outcomes for women with stage IIIC2 cervical cancer — an advanced stage where the cancer has spread to lymph nodes near the aorta (the body's main artery). **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with stage IIIC2 cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous type) - Your cancer has not spread to distant organs - You are in good general health (ECOG score 0–1) - Your blood counts and organ function meet the required levels - You are post-menopausal or using reliable contraception if of childbearing age **You may NOT be eligible if...** - Your cancer has spread beyond the pelvis to distant organs - You have received prior treatment for cervical cancer - You have an autoimmune disease or are taking immune-suppressing drugs - You are pregnant or breastfeeding - You have severe heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.